OTCMKTS:ZYXI - Zynex Stock Price, Forecast & News

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings results on Tuesday, October, 29th. The company reported $0.06 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.06 by $0.00. The company earned $11.82 million during the quarter, compared to analysts' expectations of $11.06 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's Earnings History.

Zynex is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Zynex.

Zynex issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.3-45.8 million, compared to the consensus revenue estimate of $44.11 million.

2 analysts have issued 1-year target prices for Zynex's shares. Their forecasts range from $13.00 to $19.75. On average, they anticipate Zynex's share price to reach $16.38 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price. View Analyst Price Targets for Zynex.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.

Media coverage about ZYXI stock has trended somewhat positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zynex earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Zynex.

Some companies that are related to Zynex include InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Semler Scientific (SMLR), Cutera (CUTR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include FuelCell Energy (FCEL), Melinta Therapeutics (MLNT), Altria Group (MO), Penumbra (PEN), Aldeyra Therapeutics (ALDX), BioDelivery Sciences International (BDSI), Codexis (CDXS), Catalyst Pharmaceuticals (CPRX), HEXO (HEXO) and Heron Therapeutics (HRTX).

Zynex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Punch & Associates Investment Management Inc. (1.64%), State Street Corp (0.99%), Calamos Advisors LLC (0.77%), Geode Capital Management LLC (0.68%), Cadence Capital Management LLC (0.65%) and Russell Investments Group Ltd. (0.56%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Calamos Advisors LLC, Toronto Dominion Bank and Credit Suisse AG. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.

ZYXI stock was acquired by a variety of institutional investors in the last quarter, including Punch & Associates Investment Management Inc., Bank of Montreal Can, Russell Investments Group Ltd., Renaissance Technologies LLC, State Street Corp, AQR Capital Management LLC, Bank of New York Mellon Corp and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Zynex.

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZYXI stock can currently be purchased for approximately $12.63.

Zynex has a market capitalization of $413.54 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.

The official website for Zynex is http://www.zynexmed.com/.

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]